Long-term success of GUT-directed group hypnosis for patients with refractory irritable bowel syndrome: A randomized controlled trial

American Journal of Gastroenterology

Volumn 108, Issue 4, 2013, Pages 602-609

  Moser, Gabriele ^a   Trägner, Silja ^a   Gajowniczek, Ewelina Elwira ^a   Mikulits, Andrea ^a   Michalski, Maria ^a   Kazemi Shirazi, Lili ^a   Kulnigg Dabsch, Stefanie ^a   Führer, Martina ^b   Ponocny Seliger, Elisabeth ^c   Dejaco, Clemens ^a   Miehsler, Wolfgang ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Anton Proksch Institute   (Austria)

^c SIGMUND FREUD UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ISPAGULA; PROBIOTIC AGENT; PROTON PUMP INHIBITOR; RIFAXIMIN;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CONSTIPATION; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DISEASE DURATION; FEMALE; FLATULENCE; FOLLOW UP; GROUP THERAPY; GUT DIRECTED HYPNOTHERAPY; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; HYPNOSIS; IRRITABLE COLON; LIFE SATISFACTION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PHYSICAL CAPACITY; PRIORITY JOURNAL; PSYCHOLOGICAL WELL BEING; PSYCHOTHERAPY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RELAXATION TRAINING; SHORT FORM 36; THERAPY EFFECT; TREATMENT DURATION; VISUAL ANALOG SCALE;

ADULT; ANXIETY; AUSTRIA; DEPRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPNOSIS; IRRITABLE BOWEL SYNDROME; MALE; MIDDLE AGED; PAIN MEASUREMENT; PSYCHOTHERAPY, GROUP; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84875924995     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2013.19     Document Type: Article

References (35)

1. Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology 2006; 130: 1377-90.
2. Harvey RF, Salih SY, Read AE. Organic and functional disorders in 2000 gastroenterology outpatients. Lancet 1983; 321: 632-4.
3. Mayer EA. Irritable bowel syndrome. New Engl J Med 2008; 358: 1692-29.
4. Mayer EA. Functional GI disorders: from animal models to drug development. Gut 2008; 57: 384-404.
5. Whorwell PJ, Prior A, Faragher EB. Controlled trial of hypnotherapy in the treatment of severe refractory irritable-bowel syndrome. Lancet 1984; 2: 1232-4.
6. Whorwell PJ, Prior A, Colgan SM. Hypnotherapy in severe irritable bowel syndrome: further experience. Gut 1987; 28: 423-5.
7. Gonsalkorale WM, Miller V, Afzal A et al. Long term benefits of hypnotherapy for irritable bowel sndrome. Gut 2003; 52: 1623-9.
8. Houghton LA, Heyman DJ, Whorwell PJ. Symptomatology, quality of life and economic features of irritable bowel syndrome-the Effect of hypnotherapy. Aliment Pharmacol Ther 1996; 10: 91-5.
9. Prior A, Colgan SM, Whorwell PJ. Changes in rectal sensitivity after hypnotherapy in patients with irritable bowel syndrome. Gut 1990; 31: 896-8.
10. Lea R, Houghton LA, Calvert EL et al. Gut-directed hypnotherapy normalizes disordered rectal sensitivity in patients with irritable bowel syndrome. Aliment Pharmacol Ther 2003; 17: 635-42.
11. Lackner JM, Mesmer C, Morley S et al. Psychological treatments for irritable bowel syndrome: a systematic review and meta-analysis. J Consult Clin Psychol 2004; 72: 1100-13.
12. Ford AC, Talley NJ, Schoenfeld PS et al. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut 2009; 58: 367-78.
13. Wilson S, Maddison T, Roberts L et al. Systematic review: the Effectiveness of hypnotherapy in the management of irritable bowel syndrome. Aliment Pharmacol Ther 2006; 24: 769-80.
14. Webb AN, Kukuruzovic RH, Catto-Smith AG et al. Hypnotherapy for treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2007; 17: CD005110.
15. Spiller R, Aziz Q, Creed F et al. Clinical Services Committee of The British Society of Gastroenterology. Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut 2007; 56: 1770-98.
16. Layer P, Andresen V, Pehl C et al. Irritable bowel syndrome: German consensus guidelines on definition, pathophysiology and management. Z Gastroenterol 2011; 49: 237-23.
17. Harvey RF, Hinton RA, Gunary RM et al. Individual and group hypnotherapy in treatment of refractory irritable bowel syndrome. Lancet 1989; 1: 424-5.
18. Propst A, Vogelsang H, Renner F et al Guidelines on diagnosis and therapy of the irritable bowel syndrome. Z Gastroenterol 2003; 41: 356-60.
19. Gonsalkorale WM. Gut-directed hypnotherapy: the Manchester approach for treatment of irritable bowel syndrome. Int J Clin Exp Hypn 2006; 54: 27-50.
20. Longstreth GF, Bolus R, Naliboff B et al. Impact of irritable bowel syndrome on patients'lives: development and psychometric documentation of a disease-specific measure for use in clinical trials. Eur J Gastroenterol 2005; 17: 411-20.
21. Chang L, Drossman DA. Rome foundation endpoints and outcomes conference 2009: optimizing Clinical Trials in FGID. Am J Gastroenterol 2010; 105: 722-30.
22. Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important diff erence. Control Clin Trials 1989; 4: 407-15.
23. McHorney CA, Ware JE, Raczek AE. The MOS 36-item short-form health survey (SF-36): II. Psychometric and mental health constructs. Med Care 1993; 31: 247-63.
24. McHorney CA, Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): III. Tests of data quality, scaling assumption and reliability across diverse patient groups. Med Care 1994; 32: 40-66.
25. Wagner A, Gandek B, Aaranson N et al. Cross-cultural comparison of the content of SF-36 translation across 10 countries: results from the IQOLA project. J Clin Epidemiol 1998; 51: 925-32.
26. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67: 361-70.
27. Herrmann C. International experience with the hospital anxiety and depression scale-a review of validation data and clinical results. J Psychosom Res 1997; 42: 17-41.
28. Kaptchuk TJ, Kelley JM, Conboy LA et al. Components of placebo Effect: randomised controlled trial in patients with irritable bowel syndrome. BMJ 2008; 336: 999-1003.
29. Gonsalkorale WM, Houghton LA, Whorwell PJ. Hypnotherapy in irritable bowel syndrome: a large-scale audit of a clinical service wiThexamination of factors influencing responsiveness. Am J Gastroenterol 2002; 97: 954-61.
30. Vlieger AM, Menko-Frankenhuis C, Wolfkamp SC et al. Hypnotherapy for children with functional abdominal pain or irritable bowel syndrome: a randomized controlled trial. Gastroenterology 2007; 133: 1430-6.
31. Vlieger AM, Rutten JM, Govers AM et al. Long-term follow-up of gutdirected hypnotherapy vs. standard care in children with functional abdominal pain or irritable bowel syndrome. Am J Gastroenterol 2012; 107: 627-31.
32. Lindfors P, Unge P, Nyhlin H et al. 20. Long-term Effects of hypnotherapy in patients with refractory irritable bowel syndrome. Scand J Gastroenterol 2012; 47: 414-20.
33. Blanchard EB, Lackner JM, Sanders K et al. A controlled evaluation of group cognitive therapy in the treatment of irritable bowel syndrome. Behav Res Ther 2007; 45: 633-48.
34. Flik CE, van Rood YR, Laan W et al. A randomised controlled trial on hypnotherapy for irritable bowel syndrome: design and methodological challenges (the IMAGINE study). BMC Gastroenterol 2011; 20: 137.
35. Lindfors P, Unge P, Arvidsson P et al. Effects of gut-directed hypnotherapy on IBS in diff erent clinical settings-results from two randomized, controlled trials. Am J Gastroenterol 2012; 107: 276-85.